News
Merck’s first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 ...
Halozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a ...
We recently published a list of 20 Best Stock To Buy According to Marjorie Taylor Greene. In this article, we are going to ...
Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. Read more about ...
Merck & Co (MRK) and Procter & Gamble (PG) are lower despite beating earnings expectations after lowering their guidance ...
On a per-share basis, the Rahway, New Jersey-based company said it had profit of $2.01. Earnings, adjusted for one-time gains and costs, came to $2.22 per share. The results exceeded Wall Street ...
Shares of Merck & Co. Inc. MRK advanced 1.44% to $78.97 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 2.51% to 5,287. ...
Major drugmakers like Bristol Myers Squibb, Merck & Co, Sanofi, and Roche are preparing for possible tariffs on the ...
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas ...
Companies consider production shift Roche in talks for import tariff exemptions Merck includes US$200 million tariff impact in outlook Levies could disrupt supply ...
Pharmaceuticals giant Merck & Company (MRK) has cut its full-year profit forecasts fearing a $200 million hit from President ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback